The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants
NCT ID: NCT00500305
Last Updated: 2018-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2004-04-30
2007-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Management of Patent Ductus in Premature Infants
NCT00000494
Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus
NCT00187447
Plasma B-Type Natriuretic Peptide Concentrations in Preterm Infants < 28 Weeks
NCT00528736
Indomethacin PK-PD in Extremely Preterm Neonates
NCT04025177
Brain, Gut and Kidney Blood Flow During Medical Closure of PDA
NCT00554307
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Withhold standard INDO dose if BNP < 100 pg/ml
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Infants determined by attending physician to require PDA closure
Exclusion Criteria
* infants with creatinine value \> 2.0
4 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Virginia
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
D Sc Lim, MD
Role: PRINCIPAL_INVESTIGATOR
University of Virginia
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10946
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.